Effects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin-Angiotensin-Aldosterone System Blockers

• Autori principali: Yuichiro Ueda (Autore), Hiroki Ishii (Autore), Taisuke Kitano (Autore), Mitsutoshi Shindo (Autore), Haruhisa Miyazawa (Autore), Kiyonori Ito (Autore), Keiji Hirai (Autore), Yoshio Kaku (Autore), Honami Mori (Autore), Taro Hoshino (Autore), Susumu Ookawara (Autore), Masafumi Kakei (Autore), Kaoru Tabei (Autore), Yoshiyuki Morishita (Autore)
• Natura: Libro
• Pubblicazione: AboutScience Srl, 2016-01-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Riassunto

Background We investigated the effects and safety of linagliptin as an add-on therapy in patients with advanced-stage diabetic nephropathy (DMN) taking renin-angiotensin-aldosterone system (RAAS) blockers. Method Twenty advanced-stage DMN patients (estimated glomerular filtration rate (eGFR): 24.5 ± 13.4 mL/min/1.73 m 2 ) taking RAAS blockers were administered 5 mg/day linagliptin for 52 weeks. Changes in glucose and lipid metabolism and renal function were evaluated. Results Linagliptin decreased glycosylated hemoglobin levels (from 7.32 ± 0.77% to 6.85 ± 0.87%, P < 0.05) without changing fasting blood glucose levels, and significantly decreased total cholesterol levels (from 189.6 ± 49.0 to 170.2 ± 39.2 mg/dL, P < 0.05) and low-density lipoprotein cholesterol levels (from 107.1 ± 32.4 to 90.2 ± 31.0 mg/dL, P < 0.05) without changing high-density lipoprotein cholesterol and triglyceride levels. Urine protein/creatinine ratio and annual change in eGFR remained unchanged. No adverse effects were observed. Conclusion Linagliptin as an add-on therapy had beneficial effects on glucose and lipid metabolism without impairment of renal function, and did not have any adverse effects in this population of patients with advanced-stage DMN taking RAAS blockers.

Descrizione del documento

1177-3928
10.4137/DTI.S38339